•The PBPK modeling is used in the process of Drug discovery and development.•The comprehensive PBPK model known as a whole body physiologically based pharmacokinetic (WB-PBPK) model is proposed by Dedrick and Bischoff in 1968, but did not implement and verified.•The WBPBPK model is developed with the integration of ADME models alongside the reference PBPK model.•The developed WB PBPK model is used to anticipate a systemic exposure of the drug in all compartments of the body.•The validity of the model is confirmed by the comparison of simulations of a model and clinical data of Belinostat, Allopurinol, and Paracetamol.•Preference point of this WB-PBPK model over conventional PBPK models is its prediction of concentrations of drugs as a function of time. The Physiologically based pharmacokinetic (PBPK) modeling is a supporting tool in drug discovery and improvement. Simulations produced by these models help to save time and aids in examining the effects of different variables on the pharmacokinetics of drugs. For this purpose, Sheila and Peters suggested a PBPK model capable of performing simulations to study a given drug absorption. There is a need to extend this model to the whole body entailing all another process like distribution, metabolism, and elimination, besides absorption. The aim of this scientific study is to hypothesize a WB-PBPK model through integrating absorption, distribution, metabolism, and elimination processes with the existing PBPK model.Absorption, distribution, metabolism, and elimination models are designed, integrated with PBPK model and validated. For validation purposes, clinical records of few drugs are collected from the literature. The developed WB-PBPK model is affirmed by comparing the simulations produced by the model against the searched clinical data. . It is proposed that the WB-PBPK model may be used in pharmaceutical industries to create of the pharmacokinetic profiles of drug candidates for better outcomes, as it is advance PBPK model and creates comprehensive PK profiles for drug ADME in concentration-time plots. Display omitted